Department of Laboratory Medicine and Pathology, Rochester, Minnesota.
Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Rochester, Minnesota.
Lab Med. 2021 May 4;52(3):297-302. doi: 10.1093/labmed/lmaa085.
Zinc-finger protein 384 (ZNF384) gene fusions with EP300 have recently been described as a recurrent fusion in B-cell acute lymphoblastic leukemia (B-ALL) with a good response to conventional chemotherapy, suggesting a favorable prognosis. Herein, we report on a female patient aged 12 years with uninformative conventional chromosome and B-ALL panel fluorescence in situ hybridization studies with chromosomal microarray showing multiple copy number gains, including relative gains in the ZNF384 (12p13.31) and EP300 (22q13.2) gene regions, suggesting a cryptic EP300/ZNF384 fusion. Ultimately, a next-generation sequencing assay, mate pair sequencing, was utilized to confirm EP300/ZNF384 fusion in this B-ALL clone, which may confer a favorable overall prognosis and potential targeted therapy.
锌指蛋白 384(ZNF384)基因与 EP300 的融合最近被描述为 B 细胞急性淋巴细胞白血病(B-ALL)中的一种复发性融合,对常规化疗有良好的反应,提示预后良好。在此,我们报告了一名 12 岁女性患者,其常规染色体和 B-ALL 面板荧光原位杂交研究无信息,染色体微阵列显示多个拷贝数增益,包括 ZNF384(12p13.31)和 EP300(22q13.2)基因区域的相对增益,提示存在隐匿性 EP300/ZNF384 融合。最终,使用下一代测序检测,即配对末端测序,证实了该 B-ALL 克隆中存在 EP300/ZNF384 融合,这可能赋予其有利的总体预后和潜在的靶向治疗。